General Session

Cardiovascular Disease Prevention at the Population Level

Friday, October 13, 2023

8:00 AM – 9:00 AM East Coast USA Time

Location: Palms III

Available Credits: 1 CE Hours

CME: (1) CNE: (1) ASRT: (1) COP: (1) CPHQ: (1) ACHE: (1) IPCE: (1) AAPA: (1)

Moving beyond the "one patient, one provider" model of healthcare is needed to improve cardiovascular disease outcomes at the population level. This session will provide attendees with the knowledge and insight from a community and institution (VA) perspectives needed to implement care pathways that will help shift the current paradigm.

Learning Objectives:

Recognize the concept of population health and discuss various metrics that are used to compare it across different communities.
Examine determinants of CVD at the population level, highlighting the importance of multilevel models that account for mediators and moderators of related metrics.
Evaluate innovative, data driven models currently being used to better understand population health needs and deliver targeted interventions to improve CVD outcomes.

Speaker(s)

Phillip Levy, MD, MPH

Associate VP, Translational Science
Wayne State University
Detroit, Michigan, United States

CONSULTANT FEES/HONORARIA: Bayer Healthcare Pharmaceuticals; Beckman Coulter; BTG Specialty Pharmacueticals; Cardionomics; EMCREG-International; Heart Beam; Hemisens; Ortho Diagnostics; Pathfast; Quidel Cardiovascular, Inc.; Roche Diagnostics; Siemens; UltraSight Medical

DATA SAFETY MONITORING BOARD: Life Recovery Systems

OTHER - Support for COVID-19 community surveillance testing: Quest Diagnostics

RESEARCH/RESEARCH GRANTS:Edwards Lifesciences; Pfizer Inc

Moderator(s)

David Winchester, MD, MS

Associate Professor of Medicine
University of Florida College of Medicine

I do not have any relevant financial / non-financial relationships with any proprietary interests.